证券代码：300294 证券简称：博雅生物 公告编号：2025-058 华润博雅生物制药集团股份有限公司 关于 2025 年半年度利润分配预案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 全体股东每 10 股派发现金红利 1.50 元（含税），送红股 0 股（含税），以资本 公积金向全体股东每 10 股转增 0 股。 在实施权益分派的股权登记日前，如享有利润分配权的股份总额发生变动， 则以实施分配方案时股权登记日的享有利润分配权的股份总额为基数，按照分配 比例不变的原则对分配总额进行调整。 （二）公司董事会审议情况 对、0票弃权的表决结果，审议通过《关于公司2025年半年度利润分配预案的议 案》，并同意将该议案提交公司2025年第一次临时股东大会审议，经批准后实施。 （三）公司监事会审议情况 根据中国证券监督管理委员会《上市公司监管指引第 3 号——上市公司现金 分红》及《公司章程》等规定，为充分考虑对投资者的回报，结合公司 2025 年 半年度实际生产经营情况及未来发展前景，华润博雅生物制药集团股份有限公司 （以下简称公司）于 2025 年 ...

8月22日，派斯双林生物制药股份有限公司（以下简称"派林生物（000403）"）发布2025年半年度报 告。尽管受子公司产能调整影响，公司上半年营收和净利润同比有所下滑。报告显示，今年上半年，派 林生物实现营业收入9.86亿元，同比下降13.18%；归属于上市公司股东的净利润2.36亿元，同比下降 27.89%；归属于上市公司股东的扣除非经常性损益的净利润2.15亿元，同比下降27.63%。 根据此前公司控股股东胜帮英豪与中国生物技术股份有限公司（简称"中国生物"）签署的《收购框架协 议》，正式交易文件最晚于9月10日发布。若交易完成，公司控制权将迎来重大变更，有望借助央企资 源实现战略升级。作为血液制品行业第一梯队企业，派林生物在行业集中度提升的背景下，正通过产能 优化与资本运作双轮驱动，巩固行业地位。 业绩短期调整筑根基 产能释放待下半年发力 派林生物主营业务为血液制品的研究、开发、生产和销售，血液制品属于生物制品行业的细分行业，主 要以健康人血浆为原料，采用生物学工艺或分离纯化技术制备的生物活性制剂，在医疗抢救及某些特定 疾病预防和治疗上，血液制品有着其他药品不可替代的重要作用，属于不可或缺的国家重要战 ...

8月21日消息 "国家队"国药系大动作，承诺5年内整合天坛生物与派林生物，我国血液制品行业竞争格局将被 彻底改写！ 21日晚间，中国生物收购派林集团一事迎来最新进展。天坛生物公告称，公司收到实际控制人国药集团及控股 股东中国生物出具的承诺函，因中国生物收购派林生物21.03%股份导致与公司新增同业竞争，承诺在五年内通 过包括资产置换、资产出售、资产注入、设立合资企业等方式解决同业竞争问题。同时承诺不新增与天坛生物 主营业务构成竞争的业务，并公平对待下属控股企业。该承诺函自中国生物取得派林生物控制权之日起生效。 随后派林生物收到控股股东中国生物通知，中国生物与派林生物控股股东共青城胜帮英豪投资合伙企业（有限 合伙）（"胜帮英豪"）达成合作意向并签署《收购框架协议》，约定由中国生物或其指定子公司以现金方式协 议收购胜帮英豪持有的全部21.03%派林生物股份，以取得派林生物的控制权。 值得注意的是，中国生物旗下的天坛生物与派林生物的业务重合度极高，二者均以血液制品的研究、开发、生 产和销售为主。 8月4日，天坛生物发布公告称，为避免同业竞争，公司拟放弃收购派林生物商业机会，由天坛生物控股股东中 国生物技术股份有限公 ...

Core Viewpoint - TianTan Biological (600161) is actively developing its international market presence and aims to become a globally influential blood product enterprise, aligning with China's "Belt and Road" initiative [1][2]. Group 1: International Expansion - The company does not have any production bases overseas [2]. - It is steadily advancing the international market development and registration preparations for new products [2]. - The focus is on obtaining international certifications and registrations for key products [2].

Core Viewpoint - The acquisition of Plin Biological by Tiantan Biological has faced significant developments, with Tiantan opting to abandon the opportunity, allowing its controlling shareholder, China National Biological, to pursue the acquisition independently, raising questions about the potential formation of a "giant" in the blood products industry [1][2]. Group 1: Acquisition Details - Tiantan Biological's board approved the decision to forgo the acquisition of Plin Biological, which was previously announced as a major industry deal [2]. - China National Biological plans to acquire 21.03% of Plin Biological, with a transaction price based on 3.84 billion yuan plus annual simple interest [2]. - Tiantan Biological cited "high time constraints" as a reason for abandoning the acquisition, noting the scarcity and high demand for Plin Biological's assets [2][3]. Group 2: Challenges Faced - Tiantan Biological acknowledged facing "time window" and "funding pressure" challenges, as the acquisition process requires extensive regulatory approvals, which could delay the transaction [3]. - The potential acquisition price exceeding 3.84 billion yuan poses a significant financial burden on Tiantan Biological, which has a cash balance of 2.686 billion yuan as of the end of 2024 [3]. Group 3: Business Integration Risks - The complex historical background of Plin Biological, including multiple changes in control and organizational structure, presents integration risks that could affect minority shareholders [4]. - Tiantan Biological expressed concerns about the operational risks associated with directly acquiring Plin Biological, preferring that China National Biological handle the acquisition to facilitate better strategic alignment and resource integration [4]. Group 4: Industry Perspectives - Industry experts have mixed views on China National Biological's high-premium acquisition strategy, suggesting that it still resembles a "building block" approach rather than a cohesive industry leader [5]. - The increasing number of acquisitions raises integration challenges, including management unification, cultural differences, and balancing minority shareholder interests, which are critical for China National Biological's growth as a leading player in the industry [5].

Core Viewpoint - The former chairman of Taibang Biologic, Zhou Fan, accused the current chairman, Li Hui, of misleading investors and violating laws regarding the privatization and share allocation of the company [1][2][12]. Group 1: Company Background - Taibang Biologic is one of China's top ten blood product companies, focusing on the research, production, and sales of blood and biological products [3]. - The company went public on NASDAQ in 2009, becoming the only blood product company listed in the United States [3]. Group 2: Privatization and Shareholding Issues - During the privatization process, the original management team, led by Zhou Fan, was allowed to invest in the buyout to strengthen the case for bank loans, involving over a hundred employees [2][5]. - Zhou Fan claims that the current management is attempting to cancel the shares allocated to the original management team during privatization, which he argues is illegal [2][5]. - The privatization deal was completed in April 2021, with a total valuation of approximately $4.76 billion, and Zhou Fan held about 13.77% of the shares, valued at over $656 million at the time [6][4]. Group 3: Management Changes and Conflicts - Li Hui, the current chairman, has been accused by Zhou Fan of trying to usurp control of the company through share cancellation [1][12]. - A public statement from Taibang Biologic denied Zhou Fan's claims, asserting that they would pursue legal action against him for spreading false information [2][12]. - The management structure shows that Zhou Fan is still listed as chairman, while Li Hui has taken over the role, indicating potential discrepancies in the company's governance [6][7]. Group 4: Broader Context of Li Hui and Dazhong Capital - Dazhong Capital, founded in 2016, is known for its investments in various sectors, including healthcare, and has been involved in the controversial case of Luckin Coffee, which faced a financial scandal in 2020 [9][10]. - Despite the scandal, Dazhong Capital continued to invest in Luckin Coffee, eventually becoming its controlling shareholder [10][11].

Core Viewpoint - The article discusses the results of drug production supervision inspections conducted by the Jiangxi Provincial Drug Supervision Administration from January to June 2025, highlighting compliance and non-compliance among various pharmaceutical companies [2][3][4]. Summary by Category Inspection Results - A total of 23 pharmaceutical companies were inspected during the first half of 2025, with most companies found to be compliant with the Good Manufacturing Practice (GMP) standards [2][3]. - Specific companies such as Jiangxi Ma Kang Pharmaceutical Co., Ltd. and Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd. were noted for their compliance in producing various drug forms including eye drops and traditional Chinese medicine [2][3]. Compliance Details - Companies like Jiangxi Qinfeng Pharmaceutical Co., Ltd. and Jiangxi Yichuan Pharmaceutical Technology Co., Ltd. were recognized for their adherence to GMP during inspections, covering a range of products from small volume injections to tablets [3][4]. - The inspections included checks on production lines for specific drugs, ensuring that companies met the required safety and quality standards [2][3]. Non-Compliance Issues - Some companies faced issues during inspections, although the article primarily focuses on those that complied with regulations [2][3]. - The inspections aimed to ensure that all pharmaceutical products manufactured in the province meet the necessary legal and quality standards [2][3][4].

Group 1: Administrative Law Enforcement - The provincial government is advancing a special action to standardize administrative law enforcement related to enterprises, focusing on addressing prominent issues raised by businesses to optimize the business environment and support high-quality development in Shaanxi [1] - The approach emphasizes a cycle of "rectification - standardization - enhancement," increasing efforts to investigate and rectify previously identified issues, while ensuring effective implementation of various tasks [1] - The government aims to create a coordinated "one chess game" framework, enhancing responsibility and guidance across all levels to ensure the special action is effectively implemented [1] Group 2: Food and Drug Safety - The meeting underscores the political and public significance of food and drug safety, advocating for the strictest standards, regulations, penalties, and accountability to ensure consumer safety [2] - A problem-oriented approach is emphasized, with a focus on enhancing local management responsibilities and supervision in key areas such as school canteens, farmers' markets, and emerging sectors like live-streaming sales [2] - Continuous improvement of local food and drug safety standards is encouraged to facilitate the transformation and upgrading of the province's specialty food and drug industries, thereby enhancing overall safety levels [2]

General Provisions - The company aims to protect the legal rights of shareholders and creditors, and to regulate its organization and behavior according to relevant laws [3][4] - The company is established as a foreign-invested joint-stock company under Chinese law, with a registered capital of RMB 6,637,984,837 [4][5] Business Objectives and Scope - The company's business objective is to introduce advanced technology and management methods for the production and testing of blood products, aiming to enhance production capacity and quality to international standards [5][6] - The company is engaged in the production and sale of blood products, vaccines, diagnostic reagents, and testing services, with the ability to adjust its business scope as needed [6] Shares - The company's shares are issued in the form of stocks, with a total of 6,637,984,837 shares, each with a par value of RMB 1 [7] - The issuance of shares follows principles of openness, fairness, and justice, ensuring equal rights for all shareholders of the same class [7][8] Shareholder and Shareholder Meeting - The company recognizes the rights of shareholders to receive dividends, participate in meetings, supervise operations, and transfer shares [14][16] - Shareholders holding more than 10% of shares can request the convening of a temporary shareholder meeting [25][26] Board of Directors - The board of directors is responsible for the overall management of the company, including the election and remuneration of directors and supervisors [18][19] - The board must report to the shareholders on its activities and financial performance annually [69] Financial Accounting and Auditing - The company must establish a financial accounting system and conduct internal audits, with external auditors appointed by the shareholders [8] Amendments to the Articles - The articles of association can be amended by a resolution passed at a shareholder meeting [20][21]

Core Viewpoint - The Shaanxi Provincial Drug Administration has released a plan for drug supervision and management for 2025, emphasizing the need to strengthen regulation in key varieties, links, enterprises, and regions to ensure drug quality and safety [1][2] Group 1: Regulatory Actions - Shaanxi will implement the "Qingyuan" action, focusing on drug wholesale and retail enterprises, as well as online sales, to combat illegal drug purchasing and selling channels [1] - The province aims to enhance the traceability system for drug operations, ensuring comprehensive coverage of five categories of drugs through QR code tracking [1] Group 2: Quality Supervision - Increased regulatory efforts will be directed towards vaccines, blood products, and commonly used high-value drugs, with special inspections for traditional Chinese medicine (TCM) products [1] - There will be a focus on prescription drugs and chronic disease medications, particularly in monitoring procurement channels, storage management, and information traceability [1] Group 3: Targeted Inspections - The Shaanxi Provincial Drug Administration will strengthen oversight of illegal sales of TCM formula granules and prescription drugs without proper prescriptions, as well as the absence of licensed pharmacists [2] - Special attention will be given to rural areas and small pharmacies, ensuring they have established quality management systems for drug procurement, acceptance, and storage [2] - Investigations will target issues such as substandard storage conditions and the illegal sale of TCM products, including the sale of inferior or counterfeit goods [2]